These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 29467301

  • 1. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.
    Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.
    Sci Transl Med; 2018 Feb 21; 10(429):. PubMed ID: 29467301
    [Abstract] [Full Text] [Related]

  • 2. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA, Sumi MP, Mir R, Waza AA, Bhat MA, Zuberi M, Lali P, Saxena A.
    Hum Cell; 2020 Oct 21; 33(4):1099-1111. PubMed ID: 32430672
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M, Tsuruya R, Ueda F, Ishihara A, Kasahara T, Tamura H, Tago K.
    Cytokine; 2019 Nov 21; 123():154753. PubMed ID: 31255914
    [Abstract] [Full Text] [Related]

  • 5. PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms.
    Milosevic Feenstra JD, Jäger R, Schischlik F, Ivanov D, Eisenwort G, Rumi E, Schuster M, Gisslinger B, Machherndl-Spandl S, Bettelheim P, Krauth MT, Keil F, Bock C, Cazzola M, Gisslinger H, Kralovics R, Valent P.
    Am J Hematol; 2022 Apr 21; 97(4):390-400. PubMed ID: 35015307
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M.
    Yakugaku Zasshi; 2012 Apr 21; 132(11):1267-72. PubMed ID: 23123718
    [Abstract] [Full Text] [Related]

  • 8. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
    Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.
    Blood; 2010 Dec 23; 116(26):5961-71. PubMed ID: 20870899
    [Abstract] [Full Text] [Related]

  • 9. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, Urata S, Yamauchi T, Iwamoto C, Shimoda HK, Miyamoto T, Nagafuji K, Kishimoto J, Shimoda K, Akashi K.
    Br J Haematol; 2010 Aug 23; 150(3):334-44. PubMed ID: 20553273
    [Abstract] [Full Text] [Related]

  • 10. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Wang JC, Chen C, Kundra A, Kodali S, Pandey A, Wong C, Cheung T, Gotlieb V, Joseph G, Tribie S.
    Leuk Res; 2019 Apr 23; 79():52-59. PubMed ID: 30851544
    [Abstract] [Full Text] [Related]

  • 11. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo.
    Woods B, Chen W, Chiu S, Marinaccio C, Fu C, Gu L, Bulic M, Yang Q, Zouak A, Jia S, Suraneni PK, Xu K, Levine RL, Crispino JD, Wen QJ.
    Clin Cancer Res; 2019 Oct 01; 25(19):5901-5912. PubMed ID: 31217200
    [Abstract] [Full Text] [Related]

  • 12. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
    Glück M, Dally L, Jücker M, Ehm P.
    Int J Biochem Cell Biol; 2022 Aug 01; 149():106229. PubMed ID: 35609769
    [Abstract] [Full Text] [Related]

  • 13. Programmed death-ligand 1 expression in patients with primary or secondary myelofibrosis.
    Ibrahim M, Murphree C, Patel K, Mastrodomenico M, Saba NS, Safah H, Schmid J, Socola F.
    Cancer Rep (Hoboken); 2024 Sep 01; 7(9):e2054. PubMed ID: 39233645
    [Abstract] [Full Text] [Related]

  • 14. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.
    FASEB J; 2012 Feb 01; 26(2):894-906. PubMed ID: 22051730
    [Abstract] [Full Text] [Related]

  • 15. Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
    Lewandowski K, Kanduła Z, Gniot M, Paczkowska E, Nawrocka PM, Wojtaszewska M, Janowski M, Mariak M, Handschuh L, Kozlowski P.
    Ann Hematol; 2022 Dec 01; 101(12):2665-2677. PubMed ID: 36266510
    [Abstract] [Full Text] [Related]

  • 16. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC.
    J Exp Med; 2016 Jul 25; 213(8):1479-96. PubMed ID: 27401344
    [Abstract] [Full Text] [Related]

  • 17. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS, Sarosiek KA, Lin KH, Meggendorfer M, Schnittger S, Letai A, Wood KC.
    Sci Signal; 2014 Dec 23; 7(357):ra122. PubMed ID: 25538080
    [Abstract] [Full Text] [Related]

  • 18. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.
    Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F.
    Cell Death Dis; 2018 Feb 22; 9(3):311. PubMed ID: 29472557
    [Abstract] [Full Text] [Related]

  • 19. Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2V617F cells.
    Zhou J, Guo C, Wu H, Li B, Zhou LL, Liang AB, Fu JF.
    BMC Cancer; 2021 Nov 13; 21(1):1213. PubMed ID: 34773997
    [Abstract] [Full Text] [Related]

  • 20. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.
    Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW.
    Blood; 2011 Dec 08; 118(24):6392-8. PubMed ID: 21860020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.